<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Liraglutide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB06655</strong></td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Victoza contains liraglutide, an analog of human <span class="caps">GLP</span>-1 and acts as a <span class="caps">GLP</span>-1 receptor agonist. The peptide precursor of liraglutide, produced by a process that includes expression of recombinant <span class="caps">DNA</span> in Saccharomyces cerevisiae, has been engineered to be 97% homologous to native human <span class="caps">GLP</span>-1 by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor.</p></td></tr><tr><th>Protein structure</th><td><img alt="No structure small" src="/assets/no_structure_small-e8790a148b09ecc5ad9f5b4926a538e7.png"></td></tr><tr><th>Protein chemical formula</th><td>C<sub>172</sub>H<sub>265</sub>N<sub>43</sub>O<sub>51</sub></td></tr><tr><th>Protein average weight</th><td>3751.2 Da</td></tr><tr><th>Sequences</th><td><pre class="sequence">&gt;results for sequence "results for sequence "victoza"" starting "HisAlaGluGly"
HAEGTFTSDVSSYLEGQAAKEEFIIAWLVKGRG</pre><small><a class="btn btn-info btn-sm" href="/drugs/DB06655/polypeptide_sequences.fasta">Download FASTA Format</a></small></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Arg34Lys26-(N-&#949;-(&#947;-Glu(N-&#945;-hexadecanoyl)))-GLP-1[7-37]</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>N&#178;&#8310;-(hexadecanoyl-gamma-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>N&#178;&#8310;-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide </td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>NNC 90-1170</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Victoza</td><td>Novo Nordisk</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>204656-20-2</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For use in/treatment of diabetes mellitus type 2.</td></tr><tr><th>Pharmacodynamics</th><td>Liraglutide is a once-daily GLP-1 derivative for the treatment of type 2 diabetes. GLP-1, in its natural form, is short-lived in the body (the half-life after subcutaneous injection is approximately one hour), so it is not very useful as a therapeutic agent. However, liraglutide has a half-life after subcutaneous injection of 11&#8211;15 hours, making it suitable for once-daily dosing. The prolonged action of liraglutide is achieved by attaching a fatty acid molecule at one position of the GLP-1 molecule, enabling it to bind to albumin within the subcutaneous tissue and bloodstream. The active GLP-1 is then released from albumin at a slow, consistent rate. Binding with albumin also results in slower degradation and reduced elimination of liraglutide from the circulation by the kidneys compared to GLP-1.</td></tr><tr><th>Mechanism of action</th><td>Liraglutide is an acylated GLP-1 (Glucagon-Like Peptide-1) receptor agonist. Liraglutide upregulates intracellular cAMP resulting in the release of insulin given elevated blood glucose concentrations. Glucagon secretion is also decreased in a glucose-dependent fashion by liraglutide.  </td></tr><tr><th>Absorption</th><td>Maximum concentrations of liraglutide are achieved at 8-12 hours after dose. 
The mean peak and total exposures of liraglutide were 35 ng/mL and 960 ng&#183;h/mL, respectively, for a subQ single dose of 0.6 mg. 
After subcutaneous single dose administrations, Cmax and AUC of liraglutide increased proportionally over the therapeutic dose range of 0.6 mg to 1.8 mg. At 1.8 mg Victoza, the average steady state concentration of liraglutide over 24 hours was approximately 128 ng/mL.
AUC0-&#8734; was equivalent between upper arm and abdomen, and between upper arm and thigh. AUC0-&#8734; from thigh was 22% lower than that from abdomen.  
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.</td></tr><tr><th>Volume of distribution</th><td><p>SubQ 0.6 mg is approximately 13L<br>
Intravenous is approximately 0.07L/kg</p></td></tr><tr><th>Protein binding</th><td>&gt;98%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>During the initial 24 hours following administration of a single [3H]-liraglutide dose to healthy subjects, the major component in plasma was intact liraglutide. Liraglutide is endogenously metabolized in a similar manner to large proteins without a specific organ as a major route of elimination.</p></td></tr><tr><th>Route of elimination</th><td>Excreted in urine and feces, 6% and 5%, respectively. </td></tr><tr><th>Half life</th><td>approximately 13 hours.</td></tr><tr><th>Clearance</th><td><p>The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 1.2 L/h</p></td></tr><tr><th>Toxicity</th><td>In a clinical trial, one patient with type 2 diabetes experienced a single overdose of Victoza 17.4 mg subcutaneous (10 times the maximum recommended dose). Effects of the overdose included severe nausea and vomiting requiring hospitalization. No hypoglycemia was reported. The patient recovered without complications. In the event of overdosage, appropriate supportive treatment should be initiated according to the patient&#8217;s clinical signs and symptoms.

RISK OF THYROID C-CELL TUMORS</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Novo nordisk inc</li></ul></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection</td><td>Subcutaneous</td><td>Multi-dose pen (0.6 mg, 1.2 mg, or 1.8 mg [6 mg/mL, 3 mL])</td></tr></tbody></table></td></tr><tr><th>Prices</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>6268343</td><td>1997-08-22</td><td>2017-08-22</td></tr><tr><td>Canada</td><td>2264243</td><td>2004-10-05</td><td>2017-08-22</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>liquid</td></tr><tr><th>Experimental Properties</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Russell-Jones D: Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human <span class="caps">GLP</span>-1 analogue. Mol Cell Endocrinol. 2009 Jan 15;297(1-2):137-40. Epub 2008 Nov 25. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19041364">Pubmed</a></li>
	<li>Vilsboll T: Liraglutide: a new treatment for type 2 diabetes. Drugs Today (Barc). 2009 Feb;45(2):101-13. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19343230">Pubmed</a></li>
	<li>http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=15776</li>
	<li>Malm-Erjefalt M, Bjornsdottir I, Vanggaard J, Helleberg H, Larsen U, Oosterhuis B, van Lier JJ, Zdravkovic M, Olsen AK: Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010 Nov;38(11):1944-53. doi: 10.1124/dmd.110.034066. Epub 2010 Aug 13. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20709939">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>UniProt</td><td><a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P01275" target="_blank">P01275 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA165958364" target="_blank">PA165958364 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/victoza-drug.htm" target="_blank">http://www.rxlist.com/victoza-drug.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/liraglutide.html" target="_blank">http://www.drugs.com/cdi/liraglutide.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Liraglutide" target="_blank">Liraglutide <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>A10BX07<ul class="atc-drug-tree"><li><a href="/atc/A#A">A &#8212; ALIMENTARY TRACT AND METABOLISM</a></li><li><a href="/atc/A10#A10">A10 &#8212; DRUGS USED IN DIABETES</a></li><li><a href="/atc/A10B#A10B">A10B &#8212; BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS</a></li><li><a href="/atc/A10BX#A10BX">A10BX &#8212; Other blood glucose lowering drugs, excl. insulins</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB06655.pdf?1375806744">show</a>(273 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB06655.pdf?1375808046">show</a>(569 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00316">Acetaminophen</a></td><td>These agents may have decreased C max and a delayed T max during coadministration.</td></tr><tr><td><a href="/drugs/DB01076">Atorvastatin</a></td><td>These agents may have decreased C max and a delayed T max during coadministration.</td></tr><tr><td><a href="/drugs/DB08822">Azilsartan medoxomil</a></td><td>Pharmacodynamic synergist- increases effects. May also increase hypoglycemic effects by improving insulin sensitivity. </td></tr><tr><td><a href="/drugs/DB00390">Digoxin</a></td><td>These agents may have decreased C max and a delayed T max during coadministration.</td></tr><tr><td><a href="/drugs/DB00400">Griseofulvin</a></td><td>Cmax may be increased.
</td></tr><tr><td><a href="/drugs/DB00030">Insulin Regular</a></td><td>Coadministration may increase the risk of hypoglycemia. A lower dose of the antidiabetic agent may be needed.
</td></tr><tr><td><a href="/drugs/DB00052">Somatropin recombinant</a></td><td>Somatropin may antagonize the hypoglycemic effect of liraglutide. Monitor for changes in fasting and postprandial blood sugars.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>